2022年呼吸危重症领域临床进展
本文回顾2021年10月1日至2022年9月30日呼吸危重症领域临床研究进展。发病前虚弱体质与有创机械通气中呼吸困难主诉为预后不利因素;冷冻肺活检、M-ROSE、EIT等动态监测技术有助诊断与个体化呼吸支持;巴瑞克替尼可能降低特定COVID-19危重症患者病死率;延迟抗菌治疗增加重症感染与休克病死率;NIV交替高流量氧疗降低高风险肥胖患者再插管风险;跨肺压滴定PEEP对更危重ARDS患者与更低病死率相关;ECMO联合俯卧位安全有效。
要点
- 发病前虚弱体质和有创通气中呼吸困难主诉是危重症患者预后不利因素。
- 冷冻肺活检或可提高急性低氧性呼吸衰竭患者诊断准确率并改善预后。
- M-ROSE对下呼吸道病原体有高诊断价值,在ICU应用或降低有创机械通气患者病死率。
核心结论
- 对危重症患者在动态监测和评估基础上采取个体化呼吸支持策略至关重要。
研究设计与样本
- 本文为综述,回顾2021年10月1日至2022年9月30日呼吸危重症领域临床研究进展。
主要发现
- 发病前虚弱体质是危重症患者病死率预测因素并增加ICU住院时间。
- 有创机械通气中呼吸困难主诉与创伤后应激障碍独立相关。
- 与经支气管肺活检相比,冷冻肺活检对急性低氧性呼吸衰竭患者有助提高诊断准确率并改善预后。
- M-ROSE对下呼吸道病原体有高诊断价值,在ICU应用有助降低炎症水平和有创机械通气患者病死率。
- EIT、跨肺驱动压和气道驱动压在动态评估、指导个体化呼吸支持和预后评价方面有积极意义。
关键数值与推荐
- 在已接受有创机械通气或ECMO的重症COVID-19住院患者中,巴瑞克替尼联合标准治疗(含糖皮质激素)较安慰剂可能降低病死率。
- 延迟抗菌治疗显著增加重症感染发生率和休克患者病死率。
- 拔管后立即NIV交替高流量鼻氧较单用高流量鼻氧显著降低高拔管失败风险的肥胖或超重患者再插管和死亡风险。
- 跨肺压引导PEEP较经验性高PEEP与更严重ARDS通气患者(APACHE Ⅱ>27.5)更低病死率相关。
- 静脉-静脉ECMO期间俯卧位安全有效,与90天存活和脱离ECMO更高概率相关。
临床怎么用
- 对危重症患者应基于动态监测与评估实施个体化呼吸支持策略。
- ICU可应用M-ROSE快速明确下呼吸道感染及病原体。
- 对高拔管失败风险的肥胖或超重患者,拔管后可采用NIV交替高流量鼻氧。
- 抗菌治疗时机和感染源控制对重症感染及休克患者至关重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this review, we outlined the clinical studies in critical care field of pulmonary medicine from October 1, 2021 to September 30, 2022. For critically ill patients, frailty before disease onset was a predictor of mortality with increasing ICU length of stay, and the complaints of dyspnea in intubated phase was independently associated with posttraumatic stress disorder. Compared with transbronchial lung biopsy (TBLB) for patients with acute hypoxemic respiratory failure, transbronchial lung cryobiopsy (TBLC) had a positive significance to in leading to an increased chance of establishing a more accurate diagnosis, which could significantly improve the patients' prognosis. M-ROSE (microbiological rapid on-site evaluation) had high diagnostic value for lower respiratory tract pathogens, and the application of M-ROSE in the ICU could contribute to promoting a decrease in patients' inflammation levels and reducing the mortality of patients with invasive mechanical ventilation. EIT (electrical impedance tomography), DPL (transpulmonary driving pressure) and DPaw (airway driving pressure) had excellent positive values on dynamic assessment, guiding individualized respiratory support and prognostic evaluation. In critically ill hospitalized patients with COVID-19 who had received invasive mechanical ventilation or extracorporeal membrane oxygenation, treatment with baricitinib compared with placebo (in combination with standard of care, including corticosteroids) might reduce mortality. Delayed antimicrobial treatment significantly increased the incidence of severe infection and the mortality of shock patients, however, timing of antimicrobial therapy and control of the source of infection was critical. NIV (non-invasive ventilation) alternating with high-flow nasal oxygen immediately after extubation significantly decreased the risk of reintubation and death compared with high-flow nasal oxygen alone in obese or overweight patients at high risk of extubation failure. The effect of Pes-guided positive end-expiratory pressure (PEEP), compared with empirical high PEEP, was associated with lower mortality for more severe acute respiratory distress syndrome (ARDS) ventilated patients (APACHE Ⅱ>27.5). Prone-positioning during veno-venous extracorporeal membrane oxygenation was safe and effective and was associated with a higher probability of surviving and being weaned-off extracorporeal membrane oxygenation at 90 days. Therefore, individualized respiratory support strategies based on dynamic monitoring and assessment were essential for critically ill patients. 本文回顾国内外呼吸危重症领域在2022年度(2021年10月1日到2022年9月30日)的临床进展。研究发现发病前虚弱体质和有创机械通气中呼吸困难主诉是危重症患者预后不利因素,冷冻肺活检或可有效提高危重症患者疾病诊断准确率,床旁微生物形态学快速诊断技术(M-ROSE)能够在床旁快速明确是否感染和感染致病原;电阻抗成像技术(EIT)、跨肺驱动压(DPL)、气道驱动压(DPaw)在动态评估、指导个体化呼吸支持和预后评价方面具有积极的意义;巴瑞克替尼可能对合并有高炎症反应的重症感染患者具有积极的疗效,而延迟应用抗菌素会明显增加重症感染发生率及休克患者的病死率,抗菌素应用时机和感染源控制至关重要;无创正压通气会降低拔管后高风险肥胖或超体重患者再插管风险和ICU病死率,跨肺压滴定呼气末正压(PEEP)能对病情更为危重的ARDS患者(APACHE Ⅱ>27.5)带来获益,ECMO联合俯卧位通气能够进一步改善重症ARDS患者预后,因此对危重症患者在动态监测和评估的基础上采取个体化呼吸支持策略至关重要。.
引用
- Pan P, Xie LX. [Clinical update in critical care of pulmonary medicine 2022]. Zhonghua Jie He He Hu Xi Za Zhi. 2023. PMID: 36617933. doi:10.3760/cma.j.cn112147-20221103-00873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。